reports
Ipsen showcases transformative potential of early immuno-oncology pipe...
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor typesPreclinical data show potential of Ipsen’s growing collection of investigational medicines, leveraging precision immuno‑modulation to deliver differentiated anti‑tumor activity PARIS, FRANCE, 18 ...
Ipsen présente le potentiel transformateur de son pipeline d’immuno on...
Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en charge des tumeurs solides.ITGA2 identifié comme nouvelle cible de l’anticorps-conjugué (ADC) innovant IPN60300 d’Ipsen, fortement surexprimée dans de nombreux types de tumeurs solides.Ces données précliniques illustrent le potentiel croissant du portefeuille de médicaments expé...
Ipsen - February 2026 - Monthly information relative to the total numb...
Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)28 February 2026 83,814,526 Gross total* of ...
Ipsen - Février 2026 - Information mensuelle relative au nombre total ...
Ipsen - Février 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital social Nombre total de droits de vote (1) 28 février 2...
Ipsen appoints Michelle C. Werner as EVP, President of North America
Ipsen appoints Michelle C. Werner as EVP, President of North America PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “I am very pleased to welcome Michelle to Ipsen and to the Executive Leadership Team. She brings a wealth of experience in leading teams both in the U.S. and around the world and has...
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follic...
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of seco...
Update: Ipsen retire volontairement Tazverik® (tazemetostat) dans le t...
Update: Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les indications. La décision d'Ipsen est basée sur des données émergentes issues de l'essai SYMPHONY-1 de phase Ib/III en cours (évaluant le tazemetostat en association avec le lénalidomide et le rituximab (R2) par rapport au R2 dans le lymphome folliculaire), le Comit...
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lym...
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary he...
Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitemen...
Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les indications. La décision d'Ipsen est basée sur des données émergentes issues de l'essai SYMPHONY-1 de phase Ib/III en cours (évaluant le tazemetostat en association avec le lénalidomide et le rituximab (R2) par rapport au R2 dans le lymphome folliculaire), le Comité indépe...
- Emmanuel Matot
- Stephane Houri
AKE ARKEMA
IFX INFINEON TECHNOLOGIES AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
FP TOTAL SE
VIE VEOLIA ENVIRONNEMENT SA
EDEN EDENRED SA
IPN IPSEN SA
EQNR EQUINOR ASA
SESGL SES SA FDR (CLASS A)
SREN SWISS RE AG
GALP GALP ENERGIA SGPS SA CLASS B
ENI ENI S.P.A.
01913 PRADA S.P.A.
REP REPSOL SA
SOI SOITEC SA
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
OTP OTP BANK NYRT
MELE MELEXIS NV
TIT TELECOM ITALIA S.P.A.
PRY PRYSMIAN S.P.A.
SPIE SPIE SA
FNTN FREENET AG
IDR INDRA SISTEMAS S.A. CLASS A
BP. BP P.L.C.
REY REPLY S.P.A.
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
SIGN SIG COMBIBLOC GROUP LTD
WAVE WAVESTONE SA
AG1 AUTO1 GROUP
NA9 NAGARRO
UMG UNIVERSAL MUSIC GROUP NV
DSY DASSAULT SYSTEMES SA
OVH OVH GROUPE
SHEL SHELL PLC
ARM ARM HOLDINGS PLC
EXENS EXOSENS
ALHG LOUIS HACHETTE GROUP
- Emmanuel Matot
- Stephane Houri
AKE ARKEMA
IFX INFINEON TECHNOLOGIES AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
FP TOTAL SE
VIE VEOLIA ENVIRONNEMENT SA
EDEN EDENRED SA
IPN IPSEN SA
EQNR EQUINOR ASA
SESGL SES SA FDR (CLASS A)
SREN SWISS RE AG
GALP GALP ENERGIA SGPS SA CLASS B
ENI ENI S.P.A.
01913 PRADA S.P.A.
REP REPSOL SA
SOI SOITEC SA
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
OTP OTP BANK NYRT
MELE MELEXIS NV
TIT TELECOM ITALIA S.P.A.
PRY PRYSMIAN S.P.A.
SPIE SPIE SA
FNTN FREENET AG
IDR INDRA SISTEMAS S.A. CLASS A
BP. BP P.L.C.
REY REPLY S.P.A.
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
SIGN SIG COMBIBLOC GROUP LTD
WAVE WAVESTONE SA
AG1 AUTO1 GROUP
NA9 NAGARRO
UMG UNIVERSAL MUSIC GROUP NV
DSY DASSAULT SYSTEMES SA
OVH OVH GROUPE
SHEL SHELL PLC
ARM ARM HOLDINGS PLC
EXENS EXOSENS
ALHG LOUIS HACHETTE GROUP
- Christophe-Raphaël Ganet
- Christophe-Raphaël Ganet
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...
Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...
Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...
Ipsen: 1 director
A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
- Johanna Jourdain
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
EDEN EDENRED SA
IPN IPSEN SA
PEO BANK POLSKA KASA OPIEKI SA
ADP AEROPORTS DE PARIS SA
RMS HERMES INTERNATIONAL SCA
DAI DAIMLER AG
OR L'OREAL SA
HAL HAL TRUST
EOAN E.ON SE
RWE RWE AG
SAF SAFRAN S.A.
CAP CAPGEMINI SE
HM B H&M HENNES & MAURITZ AB CLASS B
MOCORP METSO OUTOTEC OYJ
MAP MAPFRE SA
SIE SIEMENS AG
SHL SIEMENS HEALTHINEERS AG
NLBR NOVA LJUBLJANSKA BANKA DD LJUBLJANA
UN0 UNIPER SE
PLX PLUXEE NV
ULVR UNILEVER PLC
- Johanna Jourdain
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
EDEN EDENRED SA
IPN IPSEN SA
PEO BANK POLSKA KASA OPIEKI SA
ADP AEROPORTS DE PARIS SA
RMS HERMES INTERNATIONAL SCA
DAI DAIMLER AG
OR L'OREAL SA
HAL HAL TRUST
EOAN E.ON SE
RWE RWE AG
SAF SAFRAN S.A.
CAP CAPGEMINI SE
HM B H&M HENNES & MAURITZ AB CLASS B
MOCORP METSO OUTOTEC OYJ
MAP MAPFRE SA
SIE SIEMENS AG
SHL SIEMENS HEALTHINEERS AG
NLBR NOVA LJUBLJANSKA BANKA DD LJUBLJANA
UN0 UNIPER SE
PLX PLUXEE NV
ULVR UNILEVER PLC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.